2,490 results found

Canada and the European Union have established distinct frameworks for extending patent protection beyond standard terms to compensate innovators for regulatory approval delays.

The European Medicines Agency continues to be a leader in developing guidance to industry on biosimilar approvals.

On May 8, 2019, Justice Roy dismissed Servier's application for a prohibition order under the pre-amended Patented Medicines (Notice of Compliance) Regulations for Canadian Patent No

On July 10, 2019, the government of Canada published the final version of the new Patent Rules, which will come into force October 30, 2019.

Patented Medicine Prices Review Board releases August 2018 NEWSletter.

Consultation on the new MOPOP section is open until August 10, 2018.

The report of the Working Group will be presented to the PMPRB for consideration prior to the publication of draft Guidelines in the fall, followed by a further period of consultation.

In its April 2019 NEWSletter, the Patented Medicine Prices Review Board (PMPRB) announced that the Steering Committee on Guidelines Modernization would hold its final meeting on May 13, 2019, to discuss both a draft report of its deliberations and the Working Group's final report

On September 24, 2020, the Supreme Court of Canada denied leave to Apotex (Docket No. 39172) with respect to a decision affirming the quantum of profits payable to the Plaintiffs...

The Canadian Agency for Drugs and Technologies in Health (CADTH) has released a report titled Utilization of Innovator Biologics and Biosimilars for Chronic Inflammatory Diseases in Canada:...

JAMP filed an application with the Competition Tribunal on July 26, 2024, seeking leave to bring an abuse of dominance case against Janssen relating to ustekinumab (Janssen's STELARA).

On April 28, 2016, we first reported on the Competition Bureau's legal proceedings against Canadian based parka manufacturer, Moose Knuckles, concerning allegedly misleading claims...

On June 27, 2019, the Competition Bureau reached an agreement with Ticketmaster and related companies. Under the agreement, Ticketmaster L.L.C.,

On December 19, 2016, the Canadian side of the diesel engine saga plaguing VW and Audi came to a close when the federal Competition Bureau reached a consent agreement for a $15 million administrative...

In view of the ongoing COVID-19 pandemic, the Canadian Intellectual Property Office (CIPO) has further extended patent, trademark, and industrial design deadlines fixed under the relevant legislation.

Chanel S de R.L., et al. v Lam Chan Kee Company Ltd., et al. 2015 FC 1091, is a case involving counterfeit CHANEL® goods.

On June 21, 2019, Bill C-97 received Royal Assent. Bill C-97 includes amendments to the Food and Drugs Act, including a new framework for "Advanced Therapeutic Products"

The Canadian Agency for Drugs and Technologies in Health (CADTH) released Issue 8 of its Pharmaceutical Reviews Update announcing updates